'US medicines regulators have rejected a bid to get schedule-1 drug MDMA, better known as the party drug ecstasy, approved as a treatment for post-traumatic stress disorder, marking a significant setback for the nascent psychedelics sector.'

https://www.ft.com/content/520465f3-822a-4608-bcbc-3595e6235493